OPKO Health, Inc.
NASDAQ:OPKBiotechnology
+$0.01 today
- Market cap
- $1.25B
- Beta
- 1.49
- P/E (TTM)
- -5.1
- EPS (TTM)
- -$0.28
Volume 3.06M
Average 2.59M
OPK Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
OPKO Health, Inc.NASDAQ: OPK
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $2.74M rose 4.5% year over year, ahead of the -2.2% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 6.2% from the prior quarter. Over 3 fiscal years it compounded at -16.7% a year.
Context
- Stock-based compensation amounted to 1.8% of revenue in FY2025, up 0.2 pp from a year earlier.
- Stock-based compensation increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +4.5% holds above the trailing-twelve-month pace of -2.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 10.71M USD
- Year-over-year change
- -3.0%
- 4-year CAGR
- -5.8%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.71M | -3.0% |
| FY2024 | 2024-12-31 | 11.05M | -3.2% |
| FY2023 | 2023-12-31 | 11.41M | -38.3% |
| FY2022 | 2022-12-31 | 18.51M | +35.8% |
| FY2021 | 2021-12-31 | 13.63M | — |
Stock-Based Compensation vs competitors
How OPK compares with its peers on the latest reported figures
- OPK's LTM Mar 2026 stock-based compensation of $10.83M is the 8th largest of the 11 companies compared; the peer median is $28.6M.
- Its year-over-year change of -2.2% is the 5th highest of 10, against a peer median of -4.5%.
- Stock-based compensation amounts to 1.9% of revenue for OPK, versus a peer median of 7.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $381.42M | +21.6% | +32.5% | 14.1% | |
| LTM Sep 2026 | $210.96M | +32.4% | +20.6% | 16.5% | |
| LTM Mar 2026 | $44.49M | -8.9% | +8.1% | 13.1% | |
| LTM Mar 2026 | $32.2M | -31.9% | -2.6% | 3.9% | |
| LTM Mar 2026 | $29.03M | -33.3% | +6.6% | 9.1% | |
| LTM Jun 2026 | $28.16M | -29.2% | +18.8% | 3.7% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $25.54M | — | — | 6.4% |
| LTM Mar 2026 | $10.83M | -2.2% | -16.7% | 1.9% | |
| LTM Mar 2026 | $9.76M | -4.5% | -21.4% | 15.1% | |
| LTM Mar 2026 | $2.4M | +47.3% | -22.9% | 3.5% | |
| FY2025 | $2.21M | +28.2% | +36.6% | 2.0% | |
| Peer median (excluding OPK) | $28.6M | -4.5% | +8.1% | 7.7% | |
Competitors are the stored peer set for OPK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (30.14M) | (328.41M) | (188.86M) | (53.22M) | (225.68M) |
| Depreciation & Amortization | 78.72M | 108.66M | 105.3M | 98.18M | 91.63M |
| Deferred Income Tax | 10.16M | (74.41M) | 146K | 14.74M | (15M) |
| Stock-Based Compensation | 13.63M | 18.51M | 11.41M | 11.05M | 10.71M |
| Change in Working Capital | (20.48M) | 42.65M | 21.8M | 32.18M | (41.18M) |
| Accounts Receivables | 5.23M | 128.6M | 3.41M | (220K) | 30.21M |
| Inventory | 30.68M | 13.66M | 15.2M | 4.22M | (4.12M) |
| Accounts Payables | (10.85M) | (9.39M) | 2.83M | (20.66M) | (14.22M) |
| Other Working Capital | (45.55M) | (90.22M) | 363K | 48.84M | (53.06M) |
| Other Non-Cash Items | (13.55M) | 137.8M | 22.01M | (286.41M) | 976K |
| Operating Cash Flow | 38.34M | (95.19M) | (28.2M) | (183.49M) | (178.54M) |
| Capital Expenditures | (32.16M) | (24.58M) | (16.28M) | (25.01M) | (12.28M) |
| Acquisitions (Net) | (6M) | (1.76M) | (5M) | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 8.08M | 115.42M | 364K | 166.6M | 52.18M |
| Other Investing Activities | 66.03M | 1.95M | 2.71M | 210.62M | 190.39M |
| Investing Cash Flow | 35.95M | 91.04M | (18.2M) | 352.21M | 230.3M |
| Debt Repayment | (11.24M) | 23.75M | (11.03M) | 287.98M | (70.76M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | (256K) |
| Common Stock Repurchased | 0 | 0 | 0 | (90.22M) | (47.04M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 893K | (774K) | (272K) | (13.59M) | 0 |
| Financing Cash Flow | (10.35M) | 22.97M | (11.3M) | 184.17M | (118.06M) |
| Effect of Forex Changes | (1.44M) | (339K) | 388K | (3.16M) | 3.43M |
| Net Change in Cash | 62.5M | 18.48M | (57.31M) | 349.73M | (62.87M) |
| Free Cash Flow | 6.18M | (119.77M) | (44.47M) | (208.5M) | (190.82M) |
OPKO Health, Inc.
NASDAQ:OPK
Intrinsic Alpha fair value
Locked
Current Price
$1.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.